文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

鉴定与肝素诱导的血小板减少症中致病性抗体结合的血小板因子 4 氨基酸。

Characterization of platelet factor 4 amino acids that bind pathogenic antibodies in heparin-induced thrombocytopenia.

机构信息

Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada.

McMaster Centre for Transfusion Research, Hamilton, Ontario, Canada.

出版信息

J Thromb Haemost. 2019 Feb;17(2):389-399. doi: 10.1111/jth.14369.


DOI:10.1111/jth.14369
PMID:30582672
Abstract

Essentials Many patients produce antibodies but few lead to heparin-induced thrombocytopenia (HIT). Pathogenic epitopes are difficult to identify as HIT antibodies are polyclonal and polyspecific. KKO binding to platelet factor 4 (PF4) depends on 13 amino acids, three of which are newly observed. Five amino acids in PF4 can help distinguish pathogenic from non-pathogenic antibodies. SUMMARY: Background Heparin-induced thrombocytopenia (HIT) is an adverse drug reaction that results in thrombocytopenia and, in some patients, thrombotic complications. HIT is mediated by antibodies that bind to complexes of platelet factor 4 (PF4) and heparin. The antigenic epitopes of these anti-PF4/heparin antibodies have not yet been precisely defined, because of the polyspecific immune response that characterizes HIT. Objectives To identify PF4 amino acids essential for binding pathogenic HIT antibodies. Methods Alanine scanning mutagenesis was utilized to produce 70 single point mutations of PF4. Each PF4 mutant was used in an enzyme immunoassay (EIA) to test their capacity to bind a platelet-activating murine monoclonal anti-PF4/heparin antibody (KKO) and HIT patient sera (n = 9). Results and Conclusions We identified 13 amino acids that were essential for binding KKO because they directly affected either the binding site or the antigenic conformation of PF4. We also identified 10 amino acids that were required for the binding of HIT patient sera and five of these amino acids were required for binding both KKO and the HIT patient sera. The 10 amino acids required for binding HIT sera were further tested to differentiate pathogenic HIT antibodies (platelet activating, n = 45) and non-pathogenic antibodies (EIA-positive but not platelet activating, n = 28). We identified five mutations of PF4 that were recognized to be essential for binding pathogenic HIT antibodies. Using alanine scanning mutagenesis, we characterized possible binding sites of pathogenic HIT antibodies on PF4.

摘要

要点:

  • 许多患者会产生抗体,但很少导致肝素诱导的血小板减少症(HIT)。
  • 由于 HIT 抗体是多克隆和多特异性的,因此难以确定致病表位。
  • KKO 与血小板因子 4(PF4)的结合取决于 13 个氨基酸,其中 3 个是新观察到的。
  • PF4 中的 5 个氨基酸有助于区分致病和非致病抗体。

摘要:

  • 背景:肝素诱导的血小板减少症(HIT)是一种药物不良反应,可导致血小板减少,在某些患者中还会导致血栓并发症。HIT 是由与血小板因子 4(PF4)和肝素形成复合物的抗体介导的。这些抗-PF4/肝素抗体的抗原表位尚未精确定义,因为 HIT 所具有的多特异性免疫反应。
  • 目的:确定 PF4 氨基酸对结合致病 HIT 抗体的重要性。
  • 方法:利用丙氨酸扫描诱变产生了 70 个 PF4 单点突变。将每个 PF4 突变体用于酶免疫测定(EIA)中,以测试它们结合血小板激活的鼠单克隆抗-PF4/肝素抗体(KKO)和 HIT 患者血清(n=9)的能力。
  • 结果和结论:我们确定了 13 个氨基酸对 KKO 的结合至关重要,因为它们直接影响 PF4 的结合部位或抗原构象。我们还确定了 10 个氨基酸是结合 HIT 患者血清所必需的,其中 5 个氨基酸是结合 KKO 和 HIT 患者血清所必需的。进一步测试了与 HIT 血清结合所需的 10 个氨基酸,以区分致病 HIT 抗体(血小板激活,n=45)和非致病抗体(EIA 阳性但不血小板激活,n=28)。我们确定了 5 个 PF4 突变,这些突变被认为是结合致病 HIT 抗体所必需的。通过丙氨酸扫描诱变,我们对 PF4 上的致病 HIT 抗体可能的结合部位进行了特征描述。

相似文献

[1]
Characterization of platelet factor 4 amino acids that bind pathogenic antibodies in heparin-induced thrombocytopenia.

J Thromb Haemost. 2019-2

[2]
Characterization of a murine monoclonal antibody that mimics heparin-induced thrombocytopenia antibodies.

Blood. 2000-3-1

[3]
Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody.

Blood. 2002-2-15

[4]
5B9, a monoclonal antiplatelet factor 4/heparin IgG with a human Fc fragment that mimics heparin-induced thrombocytopenia antibodies.

J Thromb Haemost. 2017-9-4

[5]
Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombocytopenia.

Blood. 1998-11-1

[6]
Dimeric FcγR ectodomains detect pathogenic anti-platelet factor 4-heparin antibodies in heparin-induced thromobocytopenia.

J Thromb Haemost. 2018-11-20

[7]
Cellular immune responses to platelet factor 4 and heparin complexes in patients with heparin-induced thrombocytopenia.

J Thromb Haemost. 2018-6-5

[8]
Distinguishing between anti-platelet factor 4/heparin antibodies that can and cannot cause heparin-induced thrombocytopenia.

J Thromb Haemost. 2015-8-29

[9]
Distinct specificity and single-molecule kinetics characterize the interaction of pathogenic and non-pathogenic antibodies against platelet factor 4-heparin complexes with platelet factor 4.

J Biol Chem. 2013-10-4

[10]
Recognition of PF4-VWF complexes by heparin-induced thrombocytopenia antibodies contributes to thrombus propagation.

Blood. 2020-4-9

引用本文的文献

[1]
Role and mechanism of Integrin α5β1 in bone formation and disease.

Front Cell Dev Biol. 2025-8-14

[2]
Design of Paromomycin and Neomycin as Sulfated and Hydrophobic Glycans to Target Heparanase-Driven Tumor Progression and Metastasis.

J Med Chem. 2025-6-12

[3]
Vaccine-Induced Immune Thrombotic Thrombocytopenia: Clinicopathologic Features and New Perspectives on Anti-PF4 Antibody-Mediated Disorders.

J Clin Med. 2024-2-9

[4]
COVID-19 vaccine-induced immune thrombotic thrombocytopenia: pathophysiology and diagnosis.

Ann Hematol. 2025-1

[5]
Autoimmune Heparin-Induced Thrombocytopenia.

J Clin Med. 2023-11-3

[6]
Platelet factor 4 induces bone loss by inhibiting the integrin α5-FAK-ERK pathway.

Animal Model Exp Med. 2023-12

[7]
Vaccine-induced immune thrombotic thrombocytopenia.

Blood. 2023-4-6

[8]
Vaccine-induced immune thrombotic thrombocytopenia.

Best Pract Res Clin Haematol. 2022-9

[9]
Cloned antibodies from patients with HIT provide new clues to HIT pathogenesis.

Blood. 2023-3-2

[10]
Vaccine-induced immune thrombotic thrombocytopenia: Updates in pathobiology and diagnosis.

Front Cardiovasc Med. 2022-10-24

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索